Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Iptacopan (LNP023) for Reliable Complement Assays
2026-09-15
Learn how Iptacopan (LNP023), supplied as SKU C8699, can help distinguish complement-dependent cell damage from direct cytotoxicity in viability and hemolysis workflows. This scenario-based guide connects factor B pharmacology with practical assay design, concentration selection, data interpretation, and product reliability.
-
Proteinase K as a Protease Selectivity Benchmark
2026-09-14
Proteinase K is more than a routine digestion reagent: it can serve as a practical protease selectivity benchmark in molecular biology and inhibitor assays. This article connects SARS-CoV-2 3CLpro screening evidence with DNA workflow design, control selection, and preservation of nucleic acid quality.
-
Vancomycin as a Strategic Tool in Translational Research
2026-09-14
Vancomycin is more than a conventional comparator: its defined peptidoglycan precursor binding mechanism makes it a powerful perturbation for MRSA, resistance, and Clostridium difficile infection research. This article connects mechanism, assay design, historical comparative evidence, product handling, and translational strategy.
-
Otilonium Bromide: From Probe to Translation
2026-09-13
A mechanistic and translational framework for using Otilonium Bromide to interrogate cholinergic signaling, smooth muscle physiology, and neuroscience receptor modulation while maintaining rigorous boundaries between established evidence and forward-looking hypotheses.
-
Epoxomicin as a Probe of Proteostasis Stress
2026-09-12
Epoxomicin is a selective, irreversible proteasome inhibitor that can reveal how protein quality control responds to endoplasmic reticulum stress. This article connects its chemistry to UBR1/UBR2 biology and provides an assay-centered framework for interpreting protein degradation and disease-model data.
-
PP 2 (AG 1879) Src Signaling Workflows
2026-09-11
PP 2 (AG 1879) enables controlled interrogation of Src-family signaling in cancer, immune, and vascular models. This practical guide connects potency-aware dosing with reproducible workflows for proliferation, invasion, T-cell activation, and mechanistic validation.
-
Aurora A Overexpression in High-Risk Retinoblastoma
2026-09-11
A 2024 study identifies Aurora kinase A overexpression as a frequent feature of retinoblastoma and links it to histopathologic factors associated with aggressive disease and poor chemotherapy response. By combining patient tissue analysis with genetic, pharmacologic, cellular, and xenograft models, the work supports AURKA as a biomarker-informed therapeutic target while highlighting the need for prospective validation.
-
CK2 as a Translational Target: From Cancer to CIAV
2026-09-10
CX-4945 (Silmitasertib) offers a mechanistically grounded way to interrogate CK2 biology across oncology and host–virus research. This article connects CK2-dependent signaling, apoptosis, and cell-cycle control with new evidence that CIAV exploits host CK2α to stabilize VP2 and promote replication, while defining the experimental boundaries required for credible translation.
-
(-)-Blebbistatin: NM II Inhibition Workflows
2026-09-10
Use (-)-Blebbistatin to separate non-muscle myosin II–dependent mechanics from channel-intrinsic excitability, with practical workflows spanning live-cell imaging, migration assays, and cardiac models. Its reversible, selective profile supports paired inhibition, washout, and temperature-challenge experiments rather than endpoint-only cytoskeletal measurements.
-
GSTA1, Glutathione Depletion, and α-Amanitin Toxicity
2026-09-09
A 2026 study identifies GSTA1 as an unexpected driver of α-amanitin hepatotoxicity rather than a purely protective detoxification enzyme. Integrated animal, cellular, transcriptomic, metabolomic, docking, and DARTS evidence indicates that α-amanitin-induced GSTA1 upregulation accelerates glutathione depletion and reactive oxygen species accumulation, highlighting GSTA1 as a mechanistically relevant target in acute liver injury research.
-
SCP4, H3T3 Dephosphorylation, and Chromosome Stability
2026-09-09
The EMBO Reports study identifies SCP4 as a mitotic histone H3T3 phosphatase that balances Haspin-dependent phosphorylation, controls chromosomal passenger complex recruitment, and supports accurate chromosome segregation. Its findings connect dysregulated SCP4 activity with chromosome lagging, aneuploidy, and early embryonic mitotic failure, while suggesting experimental frameworks for studying phosphatase-dependent genome stability.
-
JHU-083 Workflows for Glutaminase Research
2026-09-08
JHU-083 enables mechanism-focused glutaminase pathway research in cerebral CD11b cells, experimental cerebral malaria models, and neuro-redox assays. This guide connects glutamate measurements with orthogonal oxidative-stress readouts while providing practical preparation, dosing, and troubleshooting strategies.
-
Fluoxetine HCl: From Serotonin to Motivation
2026-09-08
A translational perspective on how Fluoxetine HCl connects serotonergic signaling, neuroplasticity, and motivation research—and how developmental SSRI findings sharpen experimental design.
-
Low-Dose Orlistat Enhances Oxaliplatin in CRC
2026-09-07
The reference study reports that subtoxic orlistat enhanced oxaliplatin-induced cytotoxicity and apoptosis in colorectal cancer models, with activity supported by in silico synergy analysis and patient-derived xenografts. Its apoptosis-focused gene-expression analysis provides a mechanistic starting point, while the preclinical design highlights the need for further dose, toxicity, and clinical validation.
-
Dutasteride Experimental Workflows for Prostate Research
2026-09-07
Dutasteride is a dual 5-alpha-reductase inhibitor for dissecting testosterone-to-DHT signaling, growth control, and apoptosis in prostate models. This practical guide connects concentration planning, metabolite measurements, and cell-fate assays with a cross-disciplinary framework inspired by recent hepatocyte–macrophage research.